DDS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DDS is not a good buy right now for a beginner focused on long-term investing, even with $50,000-$100,000 available. The stock is trading below key trend levels, lacks a strong proprietary buy signal, has weak near-term technical momentum, and Wall Street still maintains a Sell rating. Based on the data provided, the clear decision is to avoid buying now.
Price is 547.21, essentially unchanged from the previous close, with the broader market slightly weak. The chart signals are bearish: MACD histogram is negative at -4.765 and still below zero, RSI_6 is 41.631, which is neutral but not strong enough to confirm upside, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is also below the pivot resistance zone, with pivot at 556.617 and resistance at R1 583.781. The stock trend model also points to weak forward performance, with an 80% chance of -0.45% next day, 0.03% next week, and -0.98% next month. Overall, the current price trend is weak and not an attractive long-term entry.
UBS said Dillard's may report a modest Q1 EPS beat and potentially improving same-store sales trends, which could help estimate revisions. The analyst also noted already bearish sentiment may limit downside risk. However, there were no recent news items or strong event-driven catalysts in the latest week.
No news in the recent week, no recent congress trading data, and no significant insider or hedge fund buying trends. Technical momentum is bearish, and the stock has no AI Stock Picker or SwingMax buy signal today. UBS kept a Sell rating, which reinforces negative Wall Street sentiment.
No financial snapshot was available due to a data error, so latest-quarter revenue or EPS growth cannot be verified from the provided data. The only fundamental update available is UBS's expectation for a modest Q1 EPS beat and possible improvement in same-store sales trends, which suggests some near-term operational stability but not a strong growth confirmation.
Recent analyst action was slightly more constructive on price target but still bearish overall: UBS raised its target to $465 from $460 while maintaining a Sell rating. That means the Street is still cautious, and the target remains well below the current price, showing downside bias. Pros view: possible Q1 beat and improving same-store sales could support estimates. Cons view: the rating is still Sell, sentiment is bearish, and the stock's historical volatility after earnings makes conviction weak.
